Key result
Intravenous immunoglobulin was associated with a higher left ventricular ejection fraction at 4 weeks compared to conventional therapy in adults with acute fulminant myocarditis.
Why the study?
Does intravenous immunoglobulin improve left ventricular function and reduce arrhythmias in adult patients with acute fulminant myocarditis?
Cohort (n=58)
No
Does intravenous immunoglobulin improve left ventricular function and reduce arrhythmias in adult patients with acute fulminant myocarditis?
In adult patients with acute fulminant myocarditis, IVIG therapy may be associated with improved recovery of left ventricular function and reduced episodes of fulminant arrhythmias.
Answers are grounded in this paper and cite their sources.
IVIG may aid LVEF recovery in acute fulminant myocarditis but should not yet change practice; leaves open need for randomized confirmation.
Acute fulminant myocarditis (AFM) is a serious heart disease with limited treatment. This observational retrospective study aimed to investigate whether intravenous immunoglobulin (IVIG) was able to improve left ventricular function and reduce the episodes of arrhythmia in adult patients with AFM. The medical records of all patients with AFM who were admitted to the Critical Care Unit of Guangdong General Hospital (Guangzhou, China) between January 2001 and December 2010 were reviewed. A cohort of 58 patients was included in the study. Of these 58, 32 patients were treated with IVIG (400 mg/kg per day) for five days, while the remaining patients did not receive IVIG therapy. The patients who received IVIG therapy had a higher left ventricular ejection fraction (LVEF) and a reduced left ventricular end‑diastolic diameter (LVDD) compared with the non‑IVIG therapy patients four weeks subsequent to the treatment (PLVEF=0.011 and PLVDD=0.048). The post‑treatment incidence of ventricular tachycardia/ventricular fibrillation (VT/VF) and atrioventricular block (AVB) was reduced in the patients who received IVIG therapy compared with the baseline values (PVT/VF=0.025, PAVB=0.003); however, no significant differences were observed in the non‑IVIG therapy patients (PVT/VF=0.564, PAVB=0.083) following treatment. There were two mortalities in the IVIG therapy group and seven in the non‑IVIG therapy group (P=0.072). This retrospective study suggested that the use of IVIG for the treatment of AFM may be associated with improved left ventricular function and reduced episodes of fulminant arrhythmias.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2013) conducted a cohort in Acute fulminant myocarditis (n=58). Intravenous immunoglobulin vs. Non-IVIG therapy was evaluated on Left ventricular ejection fraction (LVEF) at 4 weeks (p=0.011). Intravenous immunoglobulin was associated with a higher left ventricular ejection fraction at 4 weeks compared to conventional therapy in adults with acute fulminant myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: